9 completed, 4 recruiting, 3 terminated, 3 unknown. 12 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 5, Recruiting 3, Unknown 3, Suspended 1 |
| Phase 2 | 10 | Completed 4, Recruiting 3, Terminated 3 |
Follow T-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of T-Cell Non-Hodgkin Lymphoma trials Research Report on T-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD45BE-HSPC + CART-45 Cells CART-45 cells, CD45BE-HSPC - B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation | Phase 1 | Recruiting | University of Pennsylvania | 42 | 2026-08-05 | 2026-08-10 |
| CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas CD5 CAR-T cells infusion - T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL) | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 36 | 2025-06-01 | 2026-09-11 |
| CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas CD7 CAR-T cells infusion - T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL) | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 36 | 2025-04-01 | 2025-05-13 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances CD7 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-06-22 |
| Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies anti-CD5 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-03-02 |
| Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies ThisCART7 cells - T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | Phase 1 | Unknown | Fundamenta Therapeutics, Ltd. | 30 | 2020-01-22 | 2021-11-19 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Zilovertamab vedotin - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 91 | 2019-03-14 | 2024-01-12 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies AZD4573 - Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia | Phase 1 | Completed | AstraZeneca | 44 | 2017-10-24 | 2021-10-22 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2017-06-09 | 2019-10-21 |
| Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study - Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma | Phase 1 | Completed | Northwestern University | 15 | 2017-05-23 | 2024-06-12 |
| Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Busulfan, Fludarabine - T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell | Phase 2 | Recruiting | Keimyung University Dongsan Medical Center | 34 | 2016-12-01 | 2022-08-18 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Robert Lowsky | 18 | 2015-06-01 | 2021-06-24 |
| Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Ipilimumab, Lenalidomide - B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 41 | 2013-11-04 | 2024-12-03 |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - T-cell Non-Hodgkin Lymphoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2013-07-01 | 2023-01-30 |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine - Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 27 | 2010-09-02 | 2020-03-18 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine - CD20 Positive, Chronic Lymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 60 | 2009-02-17 | 2019-06-03 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 73 | 2008-06-25 | 2019-12-27 |
Lymphoma, T-Cell (20) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Leukemia, Myeloid, Acute (7) · Lymphoma, B-Cell (7) · Lymphoma (5) · Lymphoma, Mantle-Cell (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Lymphoma, Follicular (4) · Multiple Myeloma (4) · Myelodysplastic Syndromes (4) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4) · Hodgkin Disease (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Large B-Cell, Diffuse (3)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma, Non-Hodgkin (17) · Lymphoma (15) · Hematologic Diseases (11) · Leukemia (10) · Leukemia, Lymphoid (10) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8)
Cyclophosphamide (3) · Antilymphocyte Serum (2) · Busulfan (2) · Cyclosporine (2) · Cyclosporins (2) · Etoposide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Melphalan (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · Rituximab (2) · Whole-Body Irradiation (2) · fludarabine (2) · fludarabine phosphate (2)
Fred Hutchinson Cancer Center (3) · Beijing GoBroad Hospital (2) · M.D. Anderson Cancer Center (2) · iCell Gene Therapeutics (2) · AstraZeneca (1) · Dana-Farber Cancer Institute (1) · Fundamenta Therapeutics, Ltd. (1) · Keimyung University Dongsan Medical Center (1) · Northwestern University (1) · Robert Lowsky (1) · Roswell Park Cancer Institute (1) · University of Pennsylvania (1) · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Walter Hanel (1) · Washington University School of Medicine (1)
United States (13) · China (5) · Germany (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
David Garcia (1) · Geoffrey Uy, M.D. (1) · Hongyu Zhang (1) · Hongyu Zhang, MD/PhD (1) · Issa Khouri (1) · Issa Khouri, MD (1) · Leona Holmberg (1) · Noelle Frey, MD (1) · Philip McCarthy, MD (1) · Philippe Armand, MD (1) · Rachel Salit (1) · Robert Lowsky (1) · Tengyu Wang, Ph.D (1) · Walter Hanel, MD, PhD (1)
PMID 25145344, PMID 29246938, PMID 31699827, PMID 34398557, PMID 38319241
P30CA015704 (3), P01CA049605 (1), P30CA016672 (1), P30CA060553 (1)